Sutro Biopharma announced that REFRalphaME-L1, the global Phase 2 study of luveltamab tazevibulin for patients with non-small cell lung cancer whose tumor expresses Folate Receptor-alpha, has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025. “The initiation of REFRalphaME-L1 is an important milestone in our efforts to expand the application of luvelta to a broad range of patients with FRalpha expressing cancers. We have generated compelling preclinical evidence that luvelta can provide an important new treatment option for NSCLC, driven by its precise design, wide therapeutic window, and ability to treat patients with lower FRalpha expression profiles,” said Anne Borgman, M.D., Sutro’s Chief Medical Officer
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma price target lowered to $15 from $18 at Truist
- Sutro Biopharma reports Q2 EPS (59c), consensus (79c)
- Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
- Sutro Biopharma Appoints Sukhi Jagpal to Board and Audit Committee
- Sutro Biopharma appoints Leyman as Chief Business Development Officer